|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
Neil Vivian believes advances in electronic data collection and analysis are helping to make DCTs more accessible to broader and more diverse patient populations. Further innovations, particularly in artificial intelligence technology, are expected to accelerate these trends.
|
|
 |
|
Jeremy Guo, Senior Vice President at WuXi Biologics, and colleagues explain that many factors need to be taken into account when producing a Drug-Device Combination Product from development testing to fill/finish and assembly.
|
|
 |
|
For new drug products, it is essential that pharmaceutical companies utilize the experience of container suppliers as early as possible.
|
|
|
|
|
|
|
|
|
Nina Vas says recent challenges underscore the need for specialty logistics teams to build a flexible, anti-fragile supply chain capable of withstanding global uncertainties, and the role of knowledgeable supply chain experts has never been more significant to ensure the uninterrupted flow of essential medicines worldwide.
|
|
|
Nila Murali, Leia Jiang, and Ravali Bhavaraju highlight a promising technology that can change the way IBD is treated. Current imaging technology can successfully identify inflammation, and current treatments can address active inflammation and manage symptoms.
|
|
|
Pedro Moura Alves, PhD, reviews the intricacies of AhR immune sensing and signaling, and its potential for personalized treatment strategies to optimize therapeutic outcomes and minimize adverse effects. He also touches on some of the limitations hindering the advancement of knowledge in this crucial area of research, and the direction this emerging field may take in the coming years.
|
|
|
Mario Davinelli, PhD, Narcisa Mesaros, MD, David Morland, and Judith Neville, PhD, say therapeutic vaccines are an exciting area of research that has the potential to revolutionize the way we treat diseases.
|
|
|
Anshul Gupte, PhD, says fortunately, enhanced solubility can be achieved using a variety of approaches. For oral solid dosage forms, well-established approaches include micronization, nanoparticles, amorphous solid dispersions (ASDs), lipid-based formulations, salts, and co-crystals.
|
|
|
Mark Bleackley, PhD, says as time goes on, more companies will discover the benefits of drug repurposing – and how to successfully use such strategies to develop new, patentable drug products. In fact, repurposing could be exactly what’s needed to enable pharmaceutical and biotechnology companies to more swiftly develop treatments for indications with significant unmet medical needs.
|
|
|
|
|
|
|
|
|

Woodstock Sterile Solutions is a global provider of best-in-class sterile development and manufacturing solutions – with a decades-long track record of helping healthcare companies advance molecules through clinical development into full-scale commercial production. Throughout our 50-year history, Woodstock has been a leader in developing and deploying advanced aseptic blow-fill-seal delivery products. We recently completed the expansion of our QC analytical laboratory, doubling the size of our previous space, and building on to our analytical expertise. We have enhanced our formulation and method development capabilities to offer fully integrated drug development and manufacturing services. Click here for more.
|
|
|
|
|
|
 |
|
Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….
|
|
|
|
|
|
|
|
 |
|
A clear standard for identifying APIs susceptible to Nitrosamine Drug Substance-Related Impurities (NDSRI) formation has been elusive—until now. Adare’s team of nitrosamine experts have developed a straightforward framework that simplifies the identification of at-risk APIs. Discover how this innovative approach …
|
|
 |
|
CDMOs are emerging as critical drivers of innovation within the pharmaceutical and biotech industries. As the pharmaceutical industry continues to evolve, we can expect to see CDMOs play an increasingly important role in drug development and manufacturing. Many companies within …
|
|
 |
|
By: Mark Rauckhorst, Director Supply Chain and Project Management, Vetter Development Service USA. Inc.
Clinical trials are high-visibility milestones for investors, as this is often the first major step toward financial return on what has likely been years of investment …
|
|
 |
|
When a mid-sized pharmaceutical company asked Adare to make a version of their drug that was more convenient for patients with tremors or swallowing difficulties, our experts created a sprinkle formulation of the drug. In this CPHI Award-winning case study, …
|
|
|
|
|
Upcoming eNewsletter Features:
December 18 – Lyophilization Manufacturing
January 8 – Capsules
|
|
|
|
|
|
|
|